Does Rallies show 13F holders for CLDX?

Yes. Rallies tracks hedge fund and 13F ownership data for CLDX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CLDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLDX. It does not provide personalized investment advice.

CLDX (Celldex Therapeutics, Inc) Stock Analysis - Hedge Fund Holdings

Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of May 21, 2026, CLDX trades at $31.08 with a market cap of $2.37B and a P/E ratio of -7.83. CLDX moved +2.54% today. Year to date, CLDX is +20.70%; over the trailing twelve months it is +50.81%. Its 52-week range spans $14.40 to $35.79. Analyst consensus is strong buy with an average price target of $56.73. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CLDX stock?

Hedge funds tracked by Rallies that own CLDX include Redmile Group, Panagora Asset, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Celldex Therapeutics, Inc.

CLDX Key Metrics

Key financial metrics for CLDX
Metric	Value
Price	$31.08
Market Cap	$2.37B
P/E Ratio	-7.83
EPS	$-3.90
Dividend Yield	0.00%
52-Week High	$35.79
52-Week Low	$14.40
Volume	645.12K
Avg Volume	0
Revenue (TTM)	$1.54M
Net Income	$-258.76M
Gross Margin	87.06%

Top Hedge Funds Holding CLDX

Redmile Group holds 261.51K shares of CLDX, changed -7.69% as of Mar 31, 2026.
Panagora Asset holds 142.33K shares of CLDX, changed +551.20% as of Mar 31, 2026.
Orbimed Advisors holds 58.80K shares of CLDX, changed +0.00% as of Dec 31, 2023.

Latest CLDX News

Celldex Raises $345M and Completes Phase 3 CSU Enrollment Six Months Early — May 7, 2026
Celldex Launches Stock Offering with 15% Overallotment Option — Apr 1, 2026
Celldex Barzolvolimab Achieves 71% CSU Response, 66% ColdU Complete Rate — Mar 27, 2026
Celldex Reports $121K Revenue Miss, -$1.22 EPS and 13.01 Current Ratio — Feb 26, 2026
Celldex Finishes Enrollment Six Months Early in 1,939-Patient Phase 3 CSU Trials — Feb 25, 2026

Recent CLDX Insider Trades

Jimenez Freddy A. sold 4.17K (~$121.21K) on Dec 4, 2025.
Wright Richard M. sold 49.30K (~$1.18M) on Nov 13, 2025.
Jimenez Freddy A. sold 341 (~$8.17K) on Aug 13, 2025.

CLDX Analyst Consensus

12 analysts cover CLDX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.73.

Common questions about CLDX

Who owns CLDX stock?: Hedge funds tracked by Rallies that own CLDX include Redmile Group, Panagora Asset, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Celldex Therapeutics, Inc.
Does Rallies show 13F holders for CLDX?: Yes. Rallies tracks hedge fund and 13F ownership data for CLDX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CLDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLDX. It does not provide personalized investment advice.